A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (DIRECT)
Sponsor: Angiodynamics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS9682
U.S. Govt. ID: NCT03899636
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The study device, NanoKnife System, is being tested for the treatment of stage 3 pancreatic adenocarcinoma (cancer). The purpose of this study is to learn more about the use of the NanoKnife system for the treatment of stage 3 pancreatic cancer. The NanoKnife is a type of irreversible electroporation (IRE) device. Electroporation is a cellular destruction technology that can be used to treat cancer. It uses electrical pulses to make small holes in cells that result in cell death.
This study is closed
Investigator
Michael Kluger, MD, MPH
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have stage 3 pancreatic cancer? Yes No
Are you willing to undergo chemotherapy for the treatment of your cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE